This programme is only for New Zealand residents who have been prescribed NUCALA (mepolizumab) to help you to administer your treatment independently at home.
It is a free programme, which gives you access to a team of experienced, registered nurses who are dedicated to supporting you throughout your treatment journey. They will provide virtual training sessions to help you learn how to self-inject, and can provide you with practical advice, point you in the direction of local services, or help answer questions you might have about your treatment or about living with your condition. For more information about your treatment and medical advice consult with your healthcare professional. Any information provided here should be discussed with a HCP and does not replace a HCP’s advice.
Nucala (mepolizumab 100 mg) is a Prescription Medicine, available as a 100 mg/mL pre-filled pen (auto-injector). Nucala is used as an add-on treatment for; severe eosinophilic asthma in patients 12 years and over, severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to intranasal corticosteroids in adult patients 18 years and older, relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over, and in adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause. Nucala is given by injection under your skin (subcutaneous). Nucala is fully funded for severe eosinophilic asthma and EGPA only; Special Authority criteria apply. Use strictly as directed. Nucala has risks and benefits. Do not stop taking your other asthma medications including inhaled and /or oral steroid asthma medications.
Tell your doctor if: you have a parasitic (helminth) infection; you are taking prescription and over-the-counter medicines, vitamins, and herbal supplements; you are pregnant or plan to become pregnant; you are breastfeeding or plan to breastfeed. Nucala does not treat acute asthma symptoms, such as sudden asthma attack.
Tell your healthcare professional or get emergency help immediately if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue, breathing problems, fainting, dizziness, feeling light-headed (low blood pressure), rash or hives. Side effects: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and fatigue. Serious side effects may include allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your injection of Nucala. Allergic reactions can sometimes happen hours or days after you get a dose of Nucala. Herpes zoster infections that can cause shingles have happened in people who received Nucala. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional.
For more information, see the Nucala Consumer Medicines Information (CMI). Ask your doctor if Nucala is right for you. Normal doctor's charges apply. The NUSTART Patient Support Programme has been developed and supported by GlaxoSmithKline NZ Limited and managed by Partizan Worldwide Pty Ltd (an independent provider of patient support services). GlaxoSmithKline NZ Limited Level 2, Generator @GridAKL,12 Madden Street, Wynyard Quarter, Auckland 1010, New Zealand. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor.
TAPS NP20951 NP-NZ-MPL-PSP-240003. Date of approval: May 2024. Date of expiry: May 2026. If you have any questions regarding the NUSTART Patient Support Programme or wish to opt out you can call 0800 111 059 or write to NUSTART, 54 Victoria Street, McMahons Point NSW 2060.